US009636327B2

(12) United States Patent
Nanthakumar

(10) Patent No.: US 9,636,327 B2
(45) Date of Patent: May 2, 2017

(54) **METHODS OF ADMINISTERING DANTROLENE FOR THE ACUTE TREATMENT OF CARDIAC ARRHYTHMIAS**

(71) Applicant: **University Health Network, Toronto General Hospital**, Toronto (CA)

(72) Inventor: **Kumaraswamy Nanthakumar**, Toronto (CA)

(73) Assignee: **University Health Network**, Toronto, Ontario (CA)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/889,767**

(22) PCT Filed: **May 5, 2014**

(86) PCT No.: **PCT/IB2014/001748**

§ 371 (c)(1),
(2) Date: **Nov. 6, 2015**

(87) PCT Pub. No.: **WO2014/191837**

PCT Pub. Date: **Dec. 4, 2014**

(65) **Prior Publication Data**

US 2016/0101085 A1 Apr. 14, 2016

Related U.S. Application Data

(60) Provisional application No. 61/820,134, filed on May 6, 2013.

(51) **Int. Cl.**

A61K 31/41	(2006.01)
A61K 31/415	(2006.01)
A61K 31/4178	(2006.01)
A61K 45/06	(2006.01)
A61K 31/422	(2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/4178*** (2013.01); ***A61K 31/422*** (2013.01); ***A61K 45/06*** (2013.01)

(58) **Field of Classification Search**
CPC A61K 8/4946; C07D 263/32
USPC 514/364, 390
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,543,359 A * 9/1985 Ellis A61K 31/415 514/390

OTHER PUBLICATIONS

International Search Report and Written Opinion, dated Dec. 23, 2014, for PCT/IB2014/001748.
Kobayashi et al.; Dantrolene, a Therapeutic Agent for Malignant Hyperthermia, Markedly Improves the Function of Failing Cardiomyocytes by Stabilizing Interdomain Interactions within the Ryanodine Receptor; Journal of the American College of Cardiology (2009), vol. 53, No. 21, p. 1993-2005.
Kobayashi et al.; Dantrolene, a Therapeutic Agent for Malignant Hyperthermia, Inhibits Catecholaminergic Polymorphic Ventricular Tachycardia in a PyR2 Knock-in Mounse Model; Circulation Journal (2010), vol. 74, p. 2579-2584.
Maxwell et al; Dantrolene prevents arrythmogenic Ca2+ release in Heart Failiuer, Am J. Physiol. Heart Circ Physiol. (2012), vol. 302, No. 4, p. H953-H963.
Zamiri, et al.; Dantrolene Improves Survival After Ventricular Fibrillation by Mitigating Impaired Calcium Handling in Animal Models; Circulation 2014, vol. 130, p. 875-885.
Roden, et al.; Dantrolene: From Better Bacon to a Treatment for Ventricular Fibrillation; Circulation 2014, vol. 130., p. 834-836.
Brooks, RR, et al., "Effects of dantrolene sodium in rodent models of cardiac arrhythmia", EP Journal of Pharmacology, Elsevier Science NO., vol. 164., No. 3, May 30, 1989, pp. 521-530.

* cited by examiner

Primary Examiner — Raymond Henley, III
(74) *Attorney, Agent, or Firm* — Bryan D. Zerhusen; Locke Lord LLP

(57) **ABSTRACT**

The present description relates to methods of administering effective amounts of an anti-arrhythmic agent, e.g., dantrolene, azumolene or a pharmaceutically acceptable salt thereof, for the acute treatment of cardiac arrhythmias, e.g., atrial fibrillation, premature ventricular contraction, ventricular tachycardia or ventricular fibrillation, and prevention of subsequent cardiac arrhythmias, wherein the methods effectuate a reduction in morbidity and mortality.

16 Claims, 6 Drawing Sheets